In a recent audit of VASCU-IL-2 trial, errors lead to a correction and update of results that include loss of significance for both the decrease of cryoglobulinemia and the increase of C4 levels during administration of LD IL-2 in original report. This evidence concerns the gene IL2 and cryoglobulinemia.